Travere TherapeuticsTVTX
TVTX
About: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Employees: 385
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
71% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 28
42% more capital invested
Capital invested by funds: $1.17B [Q3] → $1.66B (+$489M) [Q4]
40% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 53
39% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $16.2M
11% more funds holding
Funds holding: 176 [Q3] → 195 (+19) [Q4]
1.67% more ownership
Funds ownership: 109.05% [Q3] → 110.72% (+1.67%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
13%
upside
Avg. target
$37
91%
upside
High target
$45
132%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Anupam Rama 24% 1-year accuracy 15 / 62 met price target | 127%upside $44 | Overweight Maintained | 26 Feb 2025 |
Citigroup Carly Kenselaar 67% 1-year accuracy 2 / 3 met price target | 80%upside $35 | Buy Maintained | 24 Feb 2025 |
Scotiabank Greg Harrison 38% 1-year accuracy 14 / 37 met price target | 65%upside $32 | Sector Outperform Maintained | 12 Feb 2025 |
Evercore ISI Group Liisa Bayko 58% 1-year accuracy 7 / 12 met price target | 132%upside $45 | Outperform Maintained | 12 Feb 2025 |
Canaccord Genuity Edward Nash 57% 1-year accuracy 12 / 21 met price target | 132%upside $45 | Buy Maintained | 12 Feb 2025 |
Financial journalist opinion
Based on 13 articles about TVTX published over the past 30 days
Neutral
GlobeNewsWire
19 hours ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 77,200 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 41,200 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 weeks ago
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March:
Neutral
Seeking Alpha
2 weeks ago
Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO William Rote - Senior Vice President of Research & Development Conference Call Participants Malcolm Kuno - JPMorgan Vamil Divan - Guggenheim Securities Joseph Schwartz - Leerink Partners Liisa Bayko - Evercore ISI Yigal Nochomovitz - Citigroup Prakhar Agrawal - Cantor Fitzgerald Fadi Ahman - Wells Fargo Gregory Harrison - Scotiabank Jason Zemansky - BofA Securities Alexander Thompson - Stifel Ed Arce - H.C. Wainwright Operator Good afternoon, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Positive
Zacks Investment Research
2 weeks ago
Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
2 weeks ago
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $1.16 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI ® (sparsentan) for FSGS
Neutral
Zacks Investment Research
3 weeks ago
Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Travere (TVTX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Neutral
GlobeNewsWire
3 weeks ago
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Positive
Zacks Investment Research
4 weeks ago
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
4 weeks ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 115,100 shares of its common stock to ten new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 79,100 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™